Securities code: Vcanbio Cell & Gene Engineering Corp.Ltd(600645) securities abbreviation: Vcanbio Cell & Gene Engineering Corp.Ltd(600645) Announcement No.: 2022014 Vcanbio Cell & Gene Engineering Corp.Ltd(600645)
Announcement on the resolutions of the 9th interim meeting of the 10th board of supervisors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Vcanbio Cell & Gene Engineering Corp.Ltd(600645) (hereinafter referred to as “the company”) the 9th interim meeting of the 10th Session of the board of supervisors was held by means of communication voting on March 26, 2022. The meeting notice and meeting materials were sent to all supervisors by email on March 21, 2022. There are 3 supervisors who should attend the meeting and 3 supervisors who actually attend the meeting. The meeting complies with the provisions of the company law and the articles of association, and the voting is valid. After careful deliberation by the supervisors present at the meeting, the following resolutions were adopted:
1. The proposal on using idle raised funds to temporarily supplement working capital was deliberated and adopted by 3 votes in favor, 0 against and 0 abstention.
In combination with the company’s production and operation needs, in order to improve the use efficiency of the raised funds and reduce the company’s financial expenses, the company plans to temporarily supplement the working capital with idle raised funds of no more than 100 million yuan without affecting the normal progress of the investment plan of the raised funds. The service life shall not exceed 12 months from the date of deliberation and approval by the board of directors of the company.
The company will timely return the idle raised funds used to supplement working capital to the special account for raised funds according to the actual progress of the investment project with raised funds and the capital demand. The temporary replenishment of working capital with idle raised funds will be used for the production and operation related to the main business. The above raised funds will not be used for the placement and purchase of new shares, or for the trading of stocks and their derivatives, convertible corporate bonds, etc. through direct or indirect arrangements, and the purpose of the raised funds will not be changed.
The board of supervisors believes that the company uses idle raised funds to supplement working capital temporarily, and the relevant procedures comply with the relevant provisions of the CSRC, such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies, the guidelines for the self discipline supervision of listed companies on Shanghai Stock Exchange No. 1 – standardized operation, and the management system of raised funds of companies; It is beneficial to improve the use efficiency of idle funds and reduce the company’s financial expenses; It does not affect the normal implementation of the company’s raised investment projects, nor does it change the purpose of the raised funds and damage the interests of the company’s shareholders, especially the minority shareholders. It is agreed that the company will use idle raised funds to supplement working capital temporarily.
For details, see the announcement of the company on using idle raised funds to temporarily supplement working capital on the same day. It is hereby announced.
Vcanbio Cell & Gene Engineering Corp.Ltd(600645) board of supervisors March 28, 2002
